Skip to main content

Ciphergen Stockholders Approve SELDI Divestiture to Bio-Rad

NEW YORK (GenomeWeb News) — Ciphergen Biosystems’ shareholders have given the company the green light to sell its proteomics instrument business to Bio-Rad Laboratories.
Under the terms of the agreement, originally disclosed in August, Ciphergen will unload the hardware branch to Bio-Rad for about $20 million in cash and a $3 million equity investment.
Ciphergen, which will now focus on its specialty diagnostic business, said it expects the deal to close before Nov. 1.
With the acquisition, Bio-Rad will be able to make and market Ciphergen’s surface enhanced laser desorption ionization technology, also known as SELDI, to the life sciences market for various proteomics applications.
Bio-Rad recently made two other purchases into the medical diagnostics market: The company bought Blackhawk Biosystems, a maker of infectious disease diagnostic products, for an undisclosed sum, and acquired Provalis’ medical diagnostic business for $3 million.
The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.